These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 19288753)

  • 1. [Status quo of the researches on HSV vaccines].
    Gao J; Lu JC; Huang YF
    Zhonghua Nan Ke Xue; 2009 Jan; 15(1):60-4. PubMed ID: 19288753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Herpes simplex virus vaccine studies: from past to present].
    Us D
    Mikrobiyol Bul; 2006 Oct; 40(4):413-33. PubMed ID: 17205702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccines for herpes simplex virus infections.
    Koelle DM
    Curr Opin Investig Drugs; 2006 Feb; 7(2):136-41. PubMed ID: 16499283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical trials of prophylactic and therapeutic herpes simplex virus vaccines.
    Stanberry LR
    Herpes; 2004 Aug; 11 Suppl 3():161A-169A. PubMed ID: 15319086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pediatrics and herpes simplex virus vaccines.
    Rupp R; Rosenthal SL; Stanberry LR
    Semin Pediatr Infect Dis; 2005 Jan; 16(1):31-7. PubMed ID: 15685147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of protective humoral immune responses against Herpes simplex virus-2 in DNA-immunized guinea-pigs using protein boosting.
    Fotouhi F; Soleimanjahi H; Roostaee MH; Behzadian F
    FEMS Immunol Med Microbiol; 2008 Oct; 54(1):18-26. PubMed ID: 18647350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An update on short-course episodic and prevention therapies for herpes genitalis.
    Corey L; Bodsworth N; Mindel A; Patel R; Schacker T; Stanberry L
    Herpes; 2007 Jun; 14 Suppl 1():5A-11A. PubMed ID: 17877886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of immunization with herpes simplex virus type-1 (HSV-1) glycoprotein D (gD) plus the immune enhancer GPI-0100 on infection with HSV-1 or HSV-2.
    Quenelle DC; Collins DJ; Marciani DJ; Kern ER
    Vaccine; 2006 Mar; 24(10):1515-22. PubMed ID: 16288820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapeutic activity of a recombinant combined gB-gD-gE vaccine against recurrent HSV-2 infections in a guinea pig model.
    Manservigi R; Boero A; Argnani R; Caselli E; Zucchini S; Miriagou V; Mavromara P; Cilli M; Grossi MP; Balboni PG; Cassai E
    Vaccine; 2005 Jan; 23(7):865-72. PubMed ID: 15603886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential prophylactic and therapeutic vaccines for HSV infections.
    Ramachandran S; Kinchington PR
    Curr Pharm Des; 2007; 13(19):1965-73. PubMed ID: 17627530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Herpes simplex virus: benefit versus risk factors in immunization.
    zur Hausen H
    Dev Biol Stand; 1979; 43():373-9. PubMed ID: 230113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Holy Grail: immune control of human herpes simplex virus infection and disease.
    Cunningham AL; Mikloska Z
    Herpes; 2001 Mar; 8 Suppl 1():6A-10A. PubMed ID: 11867028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospects for control of herpes simplex virus disease through immunization.
    Stanberry LR; Cunningham AL; Mindel A; Scott LL; Spruance SL; Aoki FY; Lacey CJ
    Clin Infect Dis; 2000 Mar; 30(3):549-66. PubMed ID: 10722443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA vaccine-encoded glycoprotein B of HSV-1 fails to protect chronic morphine-treated mice against HSV-1 challenge.
    Jamali A; Roostaee MH; Soleimanjahi H; Ghaderi Pakdel F; Bamdad T
    Comp Immunol Microbiol Infect Dis; 2007 Mar; 30(2):71-80. PubMed ID: 17126902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunology of herpes simplex virus infection: relevance to herpes simplex virus vaccines and cervical cancer.
    Nahmias AJ; Shore SL; Kohl S; Starr SE; Ashman RB
    Cancer Res; 1976 Feb; 36(2 pt 2):836-44. PubMed ID: 766960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Keratin, a dual role in herpes simplex virus pathogenesis.
    Friedman HM
    J Clin Virol; 2006 Jan; 35(1):103-5. PubMed ID: 15916917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prophylactic vaccine strategies and the potential of therapeutic vaccines against herpes simplex virus.
    Ferenczy MW
    Curr Pharm Des; 2007; 13(19):1975-88. PubMed ID: 17627531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Status of vaccine research and development of vaccines for herpes simplex virus.
    Johnston C; Gottlieb SL; Wald A
    Vaccine; 2016 Jun; 34(26):2948-2952. PubMed ID: 26973067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The ongoing pursuit of a prophylactic HSV vaccine.
    Chung E; Sen J
    Rev Med Virol; 2012 Sep; 22(5):285-300. PubMed ID: 22396215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A kinetic study of gamma interferon production in herpes simplex virus-1 DNA prime-protein boost regimen comparing to DNA or subunit vaccination].
    Arefian E; Bamdad T; Soleimanjahi H; Akhood MR; Parsania M; Ghaemi A
    Mol Biol (Mosk); 2009; 43(3):422-8. PubMed ID: 19548528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.